COVID-19: UK MHRA Says Non-Essential Inspections Will Be Office-Based
Unannounced On-Site Inspections Still On Cards To Protect Public Health
The UK’s Medicines and Healthcare products Regulatory Agency is replacing all non-essential on-site inspections with office-based assessments due to the coronavirus pandemic. The agency also plans to rely on information from international regulatory partners to maintain oversight.
You may also be interested in...
New guidance explains how UK-based sites and organizations can facilitate routine on-site good practice inspections that are due to restart next month.
Four months after suspending all non-essential on-site inspections because of the COVID-19 pandemic, the UK medicines regulator is busy finalizing the practical arrangements needed to resume these safely at local sites.
A host of European pharmaceutical industry associations, including off-patent body Medicines for Europe, has urged EU trade ministers to push back against European and global restrictions on the movement of medicines and medical equipment that are hampering the international supply chain's response to the coronavirus pandemic.